Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Drew Schnitt

Plastic Surgery Hollywood, FL Medical Doctor

NPI 1568507606 CMS profile 578474

1150 N 35Th Ave, Suite 490, Hollywood, FL 33021

Open in the dashboard

General payments

$89,341

212 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Drew Schnitt of Hollywood, FL is reported in the CMS Open Payments database as having received $89,341 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,392 14
2024 General $1,444 30
2023 General $3,995 55
2022 General $2,057 29
2021 General $13,216 19
2020 General $29,264 24
2019 General $37,974 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Drew Schnitt
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Drew Schnitt were reported at $1,392. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Drew Schnitt Plastic Surgery median Middle half National median
2019 $37,974 $371 $122–$1,483 $163
2020 $29,264 $158 $52–$438 $114
2021 $13,216 $249 $87–$752 $132
2022 $2,057 $274 $102–$793 $149
2023 $3,995 $299 $113–$891 $160
2024 $1,444 $361 $124–$1,062 $164
2025 $1,392 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Apyx Medical Corporation $45,029 16 payments
  2. Lumenis BE inc $14,791 2 payments
  3. Allergan Inc. $8,689 59 payments
  4. TEI Biosciences Inc $7,727 6 payments
  5. Lumenis, Inc $5,937 1 payment
  6. AbbVie, Inc. $1,823 35 payments
  7. Merz North America, Inc. $1,075 8 payments
  8. TELA Bio, Inc. $818 12 payments
  9. Sientra, Inc. $522 8 payments
  10. Mentor Worldwide LLC $502 8 payments
  11. Other $2,428 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $43,575 16 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,618 9 payments
  3. Food and Beverage $12,038 177 payments
  4. Travel and Lodging $3,077 6 payments
  5. Education $34 4 payments
Products named General payments · program years 2019–2025
  1. optilight $12,681 1 payment
  2. SURGIMEND $7,727 6 payments
  3. M22 $2,110 1 payment
  4. ALLODERM $1,767 8 payments
  5. NATRELLE SALINE-FILLED BREAST IMPLANTS $1,308 19 payments
  6. NATRELLE $968 15 payments
  7. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $642 9 payments
  8. Xeomin $565 4 payments
  9. BOTOX COSMETIC $535 9 payments
  10. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $522 8 payments
  11. Other $4,959 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Plastic Surgery: 39

Drug cost

$207

Median for Plastic Surgery: $219

Branded share of claims

0%

Median for Plastic Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 12 $207

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 700 Part D prescribers listed as Plastic Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $158
$158 — —
Xeomin
  • MERZ NORTH AMERICA, INC. $25
$25 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record